Literature DB >> 16254034

Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.

Takeshi Nigawara1, Yasumasa Iwasaki, Masato Asai, Masanori Yoshida, Machiko Kambayashi, Hiroshi Sashinami, Kozo Hashimoto, Toshihiro Suda.   

Abstract

Cushing's disease is characterized by persistent ACTH secretion under hypercortisolemia. In an attempt to clarify the molecular mechanism, we examined the effect of 11beta-hydroxysteroid dehydrogenase (HSD) inhibition on glucocorticoid suppression of ACTH release using murine corticotroph tumor cells. We found that 11beta-HSD2, as well as -HSD1, was expressed in the cells and that its inhibition by carbenoxolone significantly improved the negative feedback effect of glucocorticoid. Carbenoxolone also enhanced apoptosis induced by cortisol. These effects are most likely attributable to inhibition of 11beta-HSD2 because only cortisol, a substrate of 11beta-HSD2, was present in these experimental conditions. We conclude that ectopic expression of 11beta-HSD2 is, at least in part, responsible for the impaired glucocorticoid suppression in corticotroph adenoma. Inhibition of 11beta-HSD2 may be applicable to the medical therapy for Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254034     DOI: 10.1210/en.2005-0544

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.

Authors:  Takanori Ebisawa; Katsuyoshi Tojo; Naoko Tajima; Masami Kamio; Yutaka Oki; Katsuhiko Ono; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Ligand-receptor interaction between triterpenoids and the 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) enzyme predicts their toxic effects against tumorigenic r/m HM-SFME-1 cells.

Authors:  Hideaki Yamaguchi; Tao Yu; Toshiro Noshita; Yumi Kidachi; Katsuyoshi Kamiie; Kenji Yoshida; Tatsuo Akitaya; Hironori Umetsu; Kazuo Ryoyama
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

3.  Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.

Authors:  Yi Tao; Lu Gao; Xiaosong Wu; Hongmei Wang; Guang Yang; Fenghuang Zhan; Jumei Shi
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

4.  Mouse 11β-hydroxysteroid dehydrogenase type 2 for human application: homology modeling, structural analysis and ligand-receptor interaction.

Authors:  Hideaki Yamaguchi; Tatsuo Akitaya; Yumi Kidachi; Katsuyoshi Kamiie; Toshiro Noshita; Hironori Umetsu; Kazuo Ryoyama
Journal:  Cancer Inform       Date:  2011-12-01

5.  Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Rion Uchiyama; Hidekazu Koyama
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

6.  Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Yumi Nakamura; Hidekazu Koyama
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.